证券代码：600529 证券简称：山东药玻 编号：2024-071 山东省药用玻璃股份有限公司 第十届董事会第十五次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 第一部分、董事会会议召开情况 山东省药用玻璃股份有限公司（以下简称"公司"或"山东药 玻"）第十届董事会第十五次会议通知于2024年11月13日以书面结 合通讯方式向全体董事发出，会议于2024年11月25日上午9:00，在 公司研发大楼六楼会议室以现场结合通讯方式召开，会议应到董事9 名，现场实到董事5名, 4名董事以通讯方式进行表决，2名监事、董 事会秘书、财务负责人列席会议。本次会议由公司董事长召集和主 持，会议程序符合《公司法》和《公司章程》的有关规定。 第二部分、董事会会议审议情况 本次会议由公司董事长主持，以记名投票方式审议通过了《关 于公司募投项目之一年产5.6亿只预灌封注射器扩产改造项目延期的 议案》。本议案已经公司第十届董事会战略委员会2024年第一次会 议全票审议通过并提交董事会审议。 具体内容详见在上海证券交易所网站（www. ...

重要内容提示: ●山东鲁中投资有限责任公司（以下简称"鲁中投资"）持有山东省 药用玻璃股份有限公司（以下简称"本公司"、"公司"）股份数量 129,380,980 股（无限售流通股），占公司股份总数的 19.50%，为本公司 控股股东。 ●截至公告披露日，鲁中投资累计质押 58,180,000 股股份，占本公司 总股本的 8.77%,占其所持本公司股份总数的 44.97%。 公司于2024年11月19日收到鲁中投资转来的证券质押登记证明，获悉其 所持有本公司的部分股份办理了质押，具体事项如下： | 股东名 | 是否为 | 本次质押股 | 是否 | 是否 | | 质押到 | | 占其所 | 占公司 | 质押融 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 控股股 | 数 | 为限 | 补充 | 质押起始日 | 期日 | 质权人 持股份 | | 总股本 | 资资金 | | | 东 | | 售股 | 质押 | | | 比例 | 比例 | | 用途 | | 鲁中 投资 | 是 | 5,300,000 | 否 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [7]. Core Views - Despite seasonal disturbances leading to a slowdown in growth, the long-term growth potential of the company remains positive. The company is expected to benefit from product upgrades and cost reductions, maintaining its leading position in the molded bottle market [2][6]. Summary by Sections Basic Information - Company: Shandong Pharmaceutical Glass (600529.SH) - Industry: Medical Devices - Market Capitalization: 17,174.33 million CNY - Share Price: 25.88 CNY [1]. Financial Performance - For the first three quarters of 2024, the company achieved revenue of 3.83 billion CNY, a year-on-year increase of 4.1%. The net profit attributable to shareholders was 720 million CNY, up 17.3% year-on-year [2]. - The company’s revenue for 2023 is projected to be 4.98 billion CNY, with a growth rate of 19%. By 2024, revenue is expected to reach 5.64 billion CNY, reflecting a growth rate of 13% [1][6]. Profitability Metrics - The gross profit margin for the first three quarters was 32.1%, with a net profit margin of 18.8%, both showing improvements year-on-year [2]. - The report indicates a slight decline in gross margin in Q3 2024 due to a decrease in the proportion of borosilicate molded bottle shipments [2]. Cash Flow and Financial Health - The company reported a net cash flow from operating activities of 810 million CNY for the first three quarters, an increase of 11.8% year-on-year [2]. - The asset-liability ratio at the end of Q3 2024 was 22.0%, indicating a strong balance sheet with no interest-bearing debt [2]. Future Outlook - The ongoing consistency evaluation and centralized procurement are expected to support the growth of the company’s borosilicate molded bottle products. The report anticipates continued demand despite short-term seasonal fluctuations [2]. - The adjusted revenue forecasts for 2024-2026 are 5.64 billion CNY, 6.33 billion CNY, and 7.02 billion CNY, respectively, with net profits projected at 950 million CNY, 1.15 billion CNY, and 1.34 billion CNY [2][6].

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 1、山东省药用玻璃股份有限公司（以下简称"公司"）控股股东山东 鲁中投资有限责任公司（以下简称"鲁中投资"）持有公司股份总数为 129,380,980 股（无限售流通股），占公司总股本比例为 19.50%。 2、本次解除质押后，鲁中投资持有公司股份累计质押数量为 52,880,000 股，占其持股数量的比例为 40.87%，占公司总股本比例为 7.97%。 公司于 2024 年 11 月 13 日收到鲁中投资转来的中国证券登记结算有限 责任公司解除证券质押登记通知，获悉其将所持有的本公司部分股份办理 了解除质押。本次解除质押股份分别为 2023 年 11 月 7 日质押给渤海银行 股份有限公司淄博分行的 4,200,000 股和 2023 年 11 月 8 日质押给渤海银 行股份有限公司淄博分行的 1,050,000 股； 证券代码：600529 证券简称：山东药玻 编号：2024-069 山东省药用玻璃股份有限公司 关于控股股东部分股份解除质押的公告 具体 ...

重要内容提示： 证券代码：600529 证券简称：山东药玻 公告编号：2024-068 山东省药用玻璃股份有限公司 关于使用闲置募集资金购买理财产品的进展公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 到市场波动的影响，存在一定的系统性风险。公司将根据经济形势以 及金融市场的变化适时适量地介入，降低市场波动引起的投资风险。 一、本次委托理财概述 （一）投资目的 为提高募集资金使用效率，合理利用暂时闲置募集资金，在确保 不影响募集资金项目建设和使用、募集资金安全的情况下，增加公司 的收益，为公司及股东获取更多回报。 （二）投资金额 ●委托理财受托方:中国银行股份有限公司 ●委托理财金额：人民币 4,080.00 万元、人民币 3,920.00 万元 ●委托理财产品名称：人民币结构性存款【CSDVY202416966】、 人民币结构性存款【CSDVY202416967】 ●委托理财产品期限：96 天、94 天 ●履行的审议程序：公司于 2024 年 4 月 20 日召开了第十届董事 会第十二次会议和第十届监事会第十次会议 ...

证券代码：600529 证券简称：山东药玻 公告编号：2024-067 山东省药用玻璃股份有限公司 关于使用闲置募集资金购买理财产品的进展公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●委托理财受托方:中国工商银行股份有限公司 ●委托理财金额：人民币 10,000.00 万元 ●委托理财产品名称：挂钩型结构性存款【专户型 2024 年第 416 期 I 款】 ●委托理财产品期限：96 天 ●履行的审议程序：公司于 2024 年 4 月 20 日召开了第十届董事 会第十二次会议和第十届监事会第十次会议，并于 2024 年 5 月 16 日 召开了 2023 年年度股东大会，审议通过了《关于使用闲置募集资金 购买理财产品的议案》，同意公司使用总额度不超过人民币 10 亿元的 暂时闲置募集资金进行购买安全性高、流动性好、期限不超过 12 个 月（含）的保本型理财产品（包括但不限于协定性存款、结构性存款、 定期存款、通知存款、大额存单等），并在上述额度内滚动使用，募 集资金理财使用额度及授权的有效期为自议案 ...

Group 1: Business Performance - In Q3 2024, all business segments remained stable except for the subsidiary Baotou Fenghui Packaging, which experienced a decline due to the milk industry impact [2] - The company anticipates an improvement in Q4 performance compared to Q3 based on current trends [2] - October sales performance exceeded the average level of Q3 [3] Group 2: Market and Pricing Impact - The impact of the 10th batch of national centralized procurement is uncertain as the official documents are pending release, but the current market and pricing remain stable [2] - The company is closely monitoring the capital market dynamics and aims to enhance its market image and brand value [4] Group 3: Product Development and Quality - The company expects stable growth in performance and borosilicate products in 2025 [3] - The good product yield rate for borosilicate glass bottles is currently around 70%, with a 5-10% gap compared to competitors like Schott and Corning [5] Group 4: Cost Management - In Q3, the price of soda ash dropped, while energy prices rose, resulting in overall stable costs [5] Group 5: Dividend Policy - The mid-term dividend was based on stable growth to reward investors, with policies outlined in the company’s articles [5] - The company has increased the dividend ratio for 2024 [6] Group 6: Management and Incentives - The incentive fund management method has been effective in maintaining stable growth, despite concerns about the low threshold for performance growth [3] - The management's income is comparable to other listed companies and may be higher than local averages [4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 3.825 billion with a year-on-year increase of 4.1% for the first three quarters, and a net profit attributable to shareholders of 720 million, up 17.3% year-on-year [3][4]. - The decline in Q3 revenue by 1% is attributed to a significant drop in trade and carton businesses, but the demand for medium borosilicate glass continues to grow rapidly [4][5]. - The gross margin for Q3 was 31.6%, an increase of 0.9 percentage points year-on-year, benefiting from lower raw material costs [4]. - The company is expected to maintain steady growth, with a projected net profit of 930 million and 1.08 billion for 2024 and 2025, respectively, corresponding to PE ratios of 18 and 15 times [5]. Summary by Sections Financial Performance - For the first three quarters, the company achieved a gross margin of 32.1%, up 3.9 percentage points year-on-year, with a net profit margin of 18.8%, an increase of 2.1 percentage points [3]. - The company’s cash flow from operating activities was 1.048 billion in 2023, with a projected net cash flow of 885 million in 2024 [9]. Market Outlook - The demand for medium borosilicate glass is expected to improve, with the penetration rate projected to reach 30% by the end of the year [5]. - The company is well-positioned to lead the upgrade of medium borosilicate products due to its cost, technology, and customer advantages [5]. Valuation Metrics - The current stock price is 25.00, with a total share capital of 66.361 million shares and a net asset value per share of 11.74 [6]. - The company’s earnings per share (EPS) for 2023 is projected at 1.17, increasing to 1.91 by 2026 [9].

Investment Rating - The investment rating for Shandong Pharmaceutical Glass (600529) is "Buy" (maintained) [5] Core Views - The company reported a revenue of 3.83 billion yuan for the first three quarters of 2024, representing a year-over-year increase of 4.1%, and a net profit attributable to shareholders of 720 million yuan, up 17.3% year-over-year. However, Q3 2024 revenue was 1.24 billion yuan, down 1.0% year-over-year and down 6.0% quarter-over-quarter. The decline in Q3 is attributed to seasonal impacts and non-core business disruptions. The company maintains strong growth momentum and competitive advantages, with a focus on the pace of new round of centralized procurement [3][7]. Summary by Sections Financial Performance - For Q1-Q3 2024, the company achieved a gross margin of 32.1%, an increase of 3.9 percentage points year-over-year. The gross margin for Q3 2024 was 31.6%, up 0.9 percentage points year-over-year but down 2.5 percentage points quarter-over-quarter. The net profit margin for Q1-Q3 2024 was 18.8%, an increase of 2.1 percentage points year-over-year, with Q3 net profit margin at 19.8%, up 1.5 percentage points year-over-year and up 0.5 percentage points quarter-over-quarter [7][8]. Future Projections - The company expects revenues of 5.64 billion yuan, 6.50 billion yuan, and 7.59 billion yuan for 2024, 2025, and 2026 respectively, with year-over-year growth rates of 13%, 15%, and 17%. The net profit attributable to shareholders is projected to be 940 million yuan, 1.13 billion yuan, and 1.38 billion yuan for the same years, with growth rates of 22%, 20%, and 21% respectively. The earnings per share (EPS) are forecasted to be 1.42 yuan, 1.71 yuan, and 2.07 yuan for 2024, 2025, and 2026 respectively [7][8]. Market Position - The company is positioned as a leader in molded bottles, with stable growth in demand for pharmaceutical glass and continuous improvement in product structure. The expansion into new product categories and overseas markets has been effective, highlighting the importance of the company's growth momentum [3][7].

Investment Rating - The investment rating for the company is "Buy" and is maintained [2][7]. Core Views - The company reported a revenue of 3.825 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 4.12%, while the net profit attributable to the parent company was 720 million yuan, up 17.29% year-on-year [2]. - In Q3 2024, the company achieved a revenue of 1.239 billion yuan, a slight decline of 0.99% year-on-year, but the net profit for the same quarter was 245 million yuan, reflecting a year-on-year increase of 7.23% [2]. - The revenue growth has slowed down, but Q4 is expected to accelerate due to the gradual implementation of centralized procurement [2][3]. - The gross margin for Q3 2024 was 31.6%, showing a year-on-year increase of 0.9 percentage points but a decrease of 2.5 percentage points quarter-on-quarter, primarily due to product mix effects [2][3]. Financial Performance - The company forecasts revenues of 5.573 billion yuan and 6.196 billion yuan for 2024 and 2025, respectively, with year-on-year growth rates of 11.9% and 11.2% [4]. - The net profit attributable to the parent company is projected to be 948.31 million yuan in 2024 and 1.0965 billion yuan in 2025, with growth rates of 22.24% and 15.63% respectively [4]. - The earnings per share (EPS) are expected to be 1.43 yuan in 2024 and 1.65 yuan in 2025, with corresponding price-to-earnings (P/E) ratios of 17.89X and 15.48X [4][6].